Tempest Therapeutics, Inc. (TPST )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol TPST
- Company Tempest Therapeutics, Inc.
- Price $0.9
- Changes Percentage -26.03
- Change -0.315
- Day Low $0.85
- Day High $1.08
- Year High $12.23
- Year Low $0.84
- Market Cap $16,618,576
- Price Avg 50 EMA (D) $1.05
- Price Avg 200 EMA (D) $2.41
- Exchange NASDAQ
- Volume 123,053
- Average Volume 212,908
- Open $1.08
- Previous Close $1.21
- EPS -6.01
- PE -0.17
- Earnings Announcement 2026-11-04 05:00:00
- Shares Outstanding $15,979,400
Company brief: TEMPEST THERAPEUTICS, INC. (TPST )
- Healthcare
- Biotechnology
- Mr. Stephen R. Brady J.D., LLM
- https://www.tempesttx.com
- US
- N/A
- 11-12-2012
- US87978U1088
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
TPST Corporation News
Tempest Therapeutics Announces Up to $7.5 Million Private Placement
globenewswire.com -- $2.5 million upfront with up to approximately $5 million of potential aggregate gross proceeds upon the exercise in full of warrants $2.5 million upfront with up to approximately $5 million of potenti...
Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com -- BRISBANE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company pioneering the development of advanced in vivo CA...
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
globenewswire.com -- Executed a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T, with first patie...
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
globenewswire.com -- BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced chimeric antigen...
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
globenewswire.com -- BRISBANE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced chimeric antigen...
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
globenewswire.com -- BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest” or “Tempest Therapeutics”) today announced the appointment of two independent directors,...
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
globenewswire.com -- BRISBANE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell th...